VRTX · 8-K · 20261102PR000287

PALSONIFY Market Adoption

VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance 26 · Surprise 24

More than 245 million individuals have access to PALSONIFY, representing approximately 80% of U.S. covered lives. About 500 of the estimated 3,200 U.S. specialty endocrinologists who treat most people with acromegaly were prescribing the medicine at the end of the third quarter of 2026. Among patients starting or switching therapy, PALSONIFY had more than 40% brand share, which Vertex described as the leading share. PALSONIFY was approved in the EU in April 2026, with European market launches expected to begin in the second half of 2027; its Japanese regulatory submission was completed in April 2026.

Key facts

• Vertex expects to begin PALSONIFY launches in European markets in the second half of 2027. source
• More than 245 million individuals had access to PALSONIFY, representing approximately 80% of U.S. covered lives. source
• Approximately 500 of the estimated 3,200 U.S. target specialty endocrinologists were prescribing PALSONIFY at the end of third-quarter 2026. source
• PALSONIFY had a leading brand share of more than 40% among patients starting or switching therapy. source